Splenic iron decreases without change in volume or liver parameters during luspatercept therapy.

Splenic iron decreased while liver iron was stable during luspatercept therapy in some thalassemic individuals. This suggests reduction of ineffective erythropoiesis changes organ distribution of iron and demonstrates that liver iron concentration alone may not accurately reflect total body iron. Clinical trials: BEYOND: NCT03342404; BELIEVE: NCT02604433.